Role of MicroRNAs in NAFLD/NASH

被引:74
|
作者
Szabo, Gyongyi [1 ]
Csak, Timea [1 ,2 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Med, LRB215,364 Plantat St, Worcester, MA 01605 USA
[2] Brookdale Univ Hosp & Med Ctr, 1 Brookdale Plaza, Brooklyn, NY 11212 USA
关键词
MicroRNAs; NASH; NAFLD; FATTY LIVER-DISEASE; OBSTRUCTIVE SLEEP-APNEA; NONALCOHOLIC STEATOHEPATITIS; ADIPOSE-TISSUE; CIRCULATING MICRORNAS; METABOLIC SYNDROME; URIC-ACID; GUT MICROBIOTA; HEPATOCELLULAR-CARCINOMA; DIFFERENTIAL EXPRESSION;
D O I
10.1007/s10620-015-4002-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
MicroRNAs (miRNAs) are highly conserved, small, 18-25 nucleotide, non-coding RNAs that regulate gene expression at the post-transcriptional level. Each miRNA can regulate hundreds of target genes, and vice versa each target gene can be regulated by numerous miRNAs, suggesting a very complex network and explaining how miRNAs play pivotal roles in fine-tuning essentially all biological processes in all cell types in the liver. Here, we summarize the current knowledge on the role of miRNAs in the pathogenesis and diagnosis of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) with an outlook to the broader aspects of metabolic syndrome. Furthermore, we discuss the role of miRNAs as potential biomarkers and therapeutic targets in NAFLD/NASH.
引用
收藏
页码:1314 / 1324
页数:11
相关论文
共 50 条
  • [1] Role of MicroRNAs in NAFLD/NASH
    Gyongyi Szabo
    Timea Csak
    Digestive Diseases and Sciences, 2016, 61 : 1314 - 1324
  • [2] The role of the microbiome in NAFLD and NASH
    Kolodziejczyk, Aleksandra A.
    Zheng, Danping
    Shibolet, Oren
    Elinav, Eran
    EMBO MOLECULAR MEDICINE, 2019, 11 (02)
  • [3] Dual Role of MicroRNAs in NAFLD
    Ceccarelli, Sara
    Panera, Nadia
    Gnani, Daniela
    Nobili, Valerio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (04): : 8437 - 8455
  • [4] The role of IFN in the development of NAFLD and NASH
    Mohlenberg, Michelle
    Terczynska-Dyla, Ewa
    Thomsen, Karen Louise
    George, Jacob
    Eslam, Mohammed
    Gronbaek, Henning
    Hartmann, Rune
    CYTOKINE, 2019, 124
  • [5] Evolving Role for Pharmacotherapy in NAFLD/NASH
    Attia, Suzanna L.
    Softic, Samir
    Mouzaki, Marialena
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (01): : 11 - 19
  • [6] NAFLD/NASH
    Bugianesi, Elisabetta
    Petta, Salvatore
    JOURNAL OF HEPATOLOGY, 2022, 77 (02) : 549 - 550
  • [7] Deciphering the role of aberrant DNA methylation in NAFLD and NASH*
    Vachher, Meenakshi
    Bansal, Savita
    Kumar, Bhupender
    Yadav, Sandeep
    Burman, Archana
    HELIYON, 2022, 8 (10)
  • [8] Role of Exercise in NAFLD/NASH: What is the Right Prescription?
    Luis Calzadilla Bertot
    Leon Anton Adams
    Current Hepatology Reports, 2017, 16 (4) : 356 - 365
  • [9] Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
    Welch, Ryan D.
    Billon, Cyrielle
    Losby, McKenna
    Bedia-Diaz, Gonzalo
    Fang, Yuanying
    Avdagic, Amer
    Elgendy, Bahaa
    Burris, Thomas P.
    Griffett, Kristine
    METABOLITES, 2022, 12 (03)
  • [10] NAFLD/NASH and Diabetes
    Garg, Kavita
    Brackett, Scott
    Hirsch, Irl B.
    Garg, Satish K.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : S174 - S186